IRIS Accounts Production v26.1.10.61 12876486 Board of Directors 1.1.25 31.12.25 31.12.25 20.7.26 false true false false true false Auditors Opinion iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 12876486 2024-12-31 12876486 2025-12-31 12876486 2025-01-01 2025-12-31 12876486 2023-12-31 12876486 2024-01-01 2024-12-31 12876486 2024-12-31 12876486 ns15:EnglandWales 2025-01-01 2025-12-31 12876486 ns14:PoundSterling 2025-01-01 2025-12-31 12876486 ns10:Director1 2025-01-01 2025-12-31 12876486 ns10:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 12876486 ns10:SmallEntities 2025-01-01 2025-12-31 12876486 ns10:Audited 2025-01-01 2025-12-31 12876486 ns10:SmallCompaniesRegimeForDirectorsReport 2025-01-01 2025-12-31 12876486 ns10:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 12876486 ns10:FullAccounts 2025-01-01 2025-12-31 12876486 ns10:Director2 2025-01-01 2025-12-31 12876486 ns10:RegisteredOffice 2025-01-01 2025-12-31 12876486 ns5:CurrentFinancialInstruments 2025-12-31 12876486 ns5:CurrentFinancialInstruments 2024-12-31 12876486 ns5:ShareCapital 2025-12-31 12876486 ns5:ShareCapital 2024-12-31 12876486 ns5:RetainedEarningsAccumulatedLosses 2025-12-31 12876486 ns5:RetainedEarningsAccumulatedLosses 2024-12-31 12876486 ns5:ComputerEquipment 2024-12-31 12876486 ns5:ComputerEquipment 2025-01-01 2025-12-31 12876486 ns5:ComputerEquipment 2025-12-31 12876486 ns5:ComputerEquipment 2024-12-31 12876486 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-12-31 12876486 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-12-31

REGISTERED NUMBER: 12876486 (England and Wales)

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

EMVENIO CLINICAL RESEARCH U.K., LTD

EMVENIO CLINICAL RESEARCH U.K., LTD (REGISTERED NUMBER: 12876486) |

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

Page |

| Company Information | 1 |

| Statement of Financial Position | 2 |

| Notes to the Financial Statements | 3 |

| EMVENIO CLINICAL RESEARCH U.K., LTD |

COMPANY INFORMATION

FOR THE YEAR ENDED 31 DECEMBER 2025

| DIRECTORS: | G Austin

| C Fletcher

| REGISTERED OFFICE: | 6th Floor 1 London Wall

| London

| United Kingdom

| EC2Y 5EB

| REGISTERED NUMBER: | 12876486 (England and Wales)

| AUDITORS: | Byrd + Link Audit Limited

| Honeybourne Place

| Jessop Avenue

| Cheltenham

| Gloucestershire

| GL50 3SH

EMVENIO CLINICAL RESEARCH U.K., LTD (REGISTERED NUMBER: 12876486) |

STATEMENT OF FINANCIAL POSITION

31 DECEMBER 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 4 | - |  | 163 |  |

CURRENT ASSETS

Debtors: amounts falling due within one year | 5 | 391,512 |  | 231,401 |  |

Cash at bank | 94,273 |  | 97,176 |  |

485,785 |  | 328,577 |  |

CREDITORS

Amounts falling due within one year | 6 | 82,192 |  | 72,854 |  |

NET CURRENT ASSETS | 403,593 |  | 255,723 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 403,593 |  | 255,886 |  |

CAPITAL AND RESERVES

Called up share capital | 1 |  | 1 |  |

Retained earnings | 403,592 |  | 255,885 |  |

SHAREHOLDERS' FUNDS | 403,593 |  | 255,886 |  |

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 17 July 2026 and were signed on its behalf by:

C Fletcher - Director

EMVENIO CLINICAL RESEARCH U.K., LTD (REGISTERED NUMBER: 12876486) |

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

1. | STATUTORY INFORMATION

| EmVenio Clinical Research U.K., Ltd (previously known as PCM Clinical Trials International Ltd) is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life,

| - Computer equipment: 33.33%

| Financial instruments

| The company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

| Basic financial assets and liabilities that are payable or receivable within one year, typically trade payables and receivables, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

| Going concern

| The director has sought and received response from the parent company that financial support will be forthcoming for at least twelve months from approval of the financial statements. On this basis, the director continues to adopt the going concern basis of accounting in preparing the annual financial statements.

EMVENIO CLINICAL RESEARCH U.K., LTD (REGISTERED NUMBER: 12876486) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 DECEMBER 2025

2. | ACCOUNTING POLICIES - continued

| Cash and cash equivalents

| Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

| Debtors

| Short term debtors are measured at transaction price, less any impairment.

| Creditors

| Short terms creditors are measured at the transaction price.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 25 (2024 - 30 ) .

4. | TANGIBLE FIXED ASSETS

| Office

| equipment

£ |

| Cost

| At 1 January 2025 | 3,637 |  |

| Disposals | (704 | ) |

| At 31 December 2025 | 2,933 |  |

| Depreciation

| At 1 January 2025 | 3,474 |  |

| Charge for year | 163 |  |

| Eliminated on disposal | (704 | ) |

| At 31 December 2025 | 2,933 |  |

| Net book value

| At 31 December 2025 | - |  |

| At 31 December 2024 | 163 |  |

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Amounts owed by group undertakings | 375,927 |  | 195,268 |  |

| Other debtors | - |  | 18,143 |  |

| VAT | 10,087 |  | 14,872 |  |

| Prepayments | 5,498 |  | 3,118 |  |

391,512 |  | 231,401 |  |

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Corporation tax | 43,904 |  | 36,755 |  |

| Pension contributions | 4,897 |  | 20,826 |  |

| Accrued expenses | 33,391 |  | 15,273 |  |

82,192 |  | 72,854 |  |

EMVENIO CLINICAL RESEARCH U.K., LTD (REGISTERED NUMBER: 12876486) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 DECEMBER 2025

7. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

| The Report of the Auditors was unqualified.

| Nathan Smith ACA (Senior Statutory Auditor)

| for and on behalf of Byrd + Link Audit Limited

8. | PENSION COMMITMENTS

| The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £57,376 (2024 - £27,811).

| Contributions totalling £4,897 (2024 - £20,826) were payable to the fund at the reporting date and are included in creditors.

9. | RELATED PARTY DISCLOSURES

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

10. | ULTIMATE CONTROLLING PARTY

| The company is a wholly owned subsidiary of EmVenio Clinical Research, LLC, a company organized in Colorado, USA.

| The smallest and largest group in which the results of the company are consolidated is that headed by Act For Health, Inc. The consolidated financial statements may be obtained from their address at 500 East 8th Avenue, Denver CO 80203, USA.